Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BCRX 
BioCryst Pharmaceuticals Inc (BCRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BCRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -18.92% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.51B USD | Price to earnings Ratio - | 1Y Target Price 14.73 |
Price to earnings Ratio - | 1Y Target Price 14.73 | ||
Volume (30-day avg) 3751208 | Beta 1.85 | 52 Weeks Range 4.03 - 9.50 | Updated Date 04/2/2025 |
52 Weeks Range 4.03 - 9.50 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -19.72% | Operating Margin (TTM) -3.43% |
Management Effectiveness
Return on Assets (TTM) -0.16% | Return on Equity (TTM) -1925.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2002852145 | Price to Sales(TTM) 3.36 |
Enterprise Value 2002852145 | Price to Sales(TTM) 3.36 | ||
Enterprise Value to Revenue 4.44 | Enterprise Value to EBITDA 156.38 | Shares Outstanding 208960000 | Shares Floating 195089254 |
Shares Outstanding 208960000 | Shares Floating 195089254 | ||
Percent Insiders 1.41 | Percent Institutions 81.16 |
Analyst Ratings
Rating 4.27 | Target Price 15 | Buy 6 | Strong Buy 4 |
Buy 6 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BioCryst Pharmaceuticals Inc
Company Overview
History and Background
BioCryst Pharmaceuticals, Inc. was founded in 1986. Initially focused on structure-guided drug design, it has evolved into a commercial-stage biopharmaceutical company developing and marketing novel, oral medicines to treat rare diseases.
Core Business Areas
- Hereditary Angioedema (HAE): Development and commercialization of oral treatments for HAE, primarily ORLADEYO (berotralstat).
- Other Rare Diseases: Research and development of other potential treatments for rare diseases.
- Discovery research: Focus on discovering more therapies using structure-guided drug design, which combines X-ray crystallography, computational modeling and medicinal chemistry to discover drugs for diseases with unmet needs.
Leadership and Structure
Jon Stonehouse is the CEO. The organizational structure includes research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- ORLADEYO (berotralstat): An oral, once-daily therapy for the prevention of HAE attacks. ORLADEYO is the key revenue generator for BioCryst. Competitors include Takeda's TAKHZYRO (lanadelumab) and CSL Behring's HAEGARDA (C1-esterase inhibitor). Estimated market share in oral HAE prevention is significant, but fluctuates based on competitive dynamics and patient adoption. Revenue figures from ORLADEYO account for nearly all of BioCryst's total revenue.
Market Dynamics
Industry Overview
The biopharmaceutical industry, especially in rare diseases, is characterized by high development costs, regulatory hurdles, and potential for high returns. The HAE market is competitive, with established injectable therapies and newer oral options.
Positioning
BioCryst is positioned as an innovator in oral therapies for rare diseases, offering patients a more convenient treatment option compared to traditional injectables. Its competitive advantage lies in the oral administration of ORLADEYO and a growing pipeline of other potential rare disease treatments.
Total Addressable Market (TAM)
The HAE market is estimated to be multi-billion USD. BioCryst aims to capture a significant share of this market with ORLADEYO and is expanding to capture an increasing market share of the TAM for rare diseases.
Upturn SWOT Analysis
Strengths
- Novel oral therapy (ORLADEYO)
- Strong intellectual property protection
- Experienced management team
- Focus on rare diseases with unmet needs
Weaknesses
- Reliance on a single key product (ORLADEYO)
- Competition from established injectable therapies
- Potential for generic competition in the future
- High R&D costs
Opportunities
- Expansion into new markets
- Development of new indications for ORLADEYO
- Acquisition or licensing of new rare disease assets
- Expansion of oral therapies
Threats
- Regulatory setbacks
- Clinical trial failures
- Competition from new therapies
- Pricing pressures
Competitors and Market Share
Key Competitors
- TAK
- CSL
Competitive Landscape
BioCryst benefits from ORLADEYOu2019s oral administration, offering convenience compared to injectables. However, competitors like TAK and CSL have established brands and market presence, leading to intense competition.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to regulatory approvals and market adoption of ORLADEYO.
Future Projections: Future growth projections are based on continued ORLADEYO sales growth, potential new indications, and pipeline development.
Recent Initiatives: Recent strategic initiatives include expanding ORLADEYO's global reach and advancing the pipeline of other rare disease treatments.
Summary
BioCryst is a biopharmaceutical company showing promise with ORLADEYO and pipeline expansion; Its dependence on one product and facing competition from large pharmaceuticals remains a challenge. However, strong growth trajectory and strategic initiatives present growth potential. Future performance depends on ORLADEYO's continued success and pipeline development.
Similar Companies
CSL
Carlisle Companies Incorporated
CSL
Carlisle Companies Incorporated
HALO
Halozyme Therapeutics Inc
HALO
Halozyme Therapeutics Inc
TAK
Takeda Pharmaceutical Co Ltd ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
Sources and Disclaimers
Data Sources:
- BioCryst Pharmaceuticals Investor Relations
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share estimates are approximate and subject to change. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioCryst Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 1994-03-03 | CEO, President & Executive Director Mr. Jon P. Stonehouse | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 580 | Website https://www.biocryst.com |
Full time employees 580 | Website https://www.biocryst.com | ||
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.